Benitec Biopharma (BNTC) News Today $10.68 +0.28 (+2.69%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Simplify Asset Management Inc. Grows Position in Benitec Biopharma Inc. (NASDAQ:BNTC)Simplify Asset Management Inc. boosted its position in Benitec Biopharma Inc. (NASDAQ:BNTC - Free Report) by 127.5% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 116,535 shares of the biotechnology company's stock after purchasing an additional 65November 15 at 11:16 AM | marketbeat.comBenitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational UpdateNovember 14 at 4:30 PM | globenewswire.comBenitec Biopharma Inc. (NASDAQ:BNTC) Short Interest UpdateBenitec Biopharma Inc. (NASDAQ:BNTC - Get Free Report) saw a significant increase in short interest during the month of October. As of October 31st, there was short interest totalling 56,900 shares, an increase of 49.0% from the October 15th total of 38,200 shares. Based on an average daily trading volume, of 28,900 shares, the days-to-cover ratio is presently 2.0 days.November 14 at 7:38 AM | marketbeat.comBenitec Biopharma Inc. (NASDAQ:BNTC) Receives Consensus Rating of "Buy" from AnalystsNovember 10, 2024 | americanbankingnews.comBenitec Biopharma Inc. (NASDAQ:BNTC) Receives Average Recommendation of "Buy" from AnalystsBenitec Biopharma Inc. (NASDAQ:BNTC - Get Free Report) has been assigned a consensus recommendation of "Buy" from the six ratings firms that are currently covering the company, Marketbeat reports. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating on theNovember 10, 2024 | marketbeat.comBenitec Biopharma CEO to Participate in the Guggenheim Securities Healthcare ConferenceNovember 4, 2024 | globenewswire.comBenitec Biopharma files $125M mixed securities shelfNovember 1, 2024 | markets.businessinsider.comBenitec Biopharma (BNTC) Receives a Buy from Piper SandlerOctober 19, 2024 | markets.businessinsider.comBenitec Biopharma: OPMD Program Continues To Advance With CatalystsOctober 17, 2024 | seekingalpha.comBenitec Biopharma Inc. (NASDAQ:BNTC) to Post Q1 2025 Earnings of ($0.54) Per Share, Leerink Partnrs ForecastsBenitec Biopharma Inc. (NASDAQ:BNTC - Free Report) - Analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Benitec Biopharma in a report released on Monday, October 14th. Leerink Partnrs analyst M. Foroohar anticipates that the biotechnology company will post earningsOctober 17, 2024 | marketbeat.comOppenheimer Initiates Coverage of Benitec Biopharma (BNTC) with Outperform RecommendationOctober 17, 2024 | msn.comBenitec Biopharma Inc. (NASDAQ:BNTC) Receives Consensus Recommendation of "Buy" from BrokeragesBenitec Biopharma Inc. (NASDAQ:BNTC - Get Free Report) has been given an average rating of "Buy" by the five research firms that are covering the company, MarketBeat.com reports. Four analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the compOctober 16, 2024 | marketbeat.comBenitec Biopharma (NASDAQ:BNTC) Now Covered by OppenheimerOppenheimer assumed coverage on shares of Benitec Biopharma in a research report on Wednesday. They issued an "outperform" rating and a $35.00 price target for the company.October 16, 2024 | marketbeat.comBuy Rating Affirmed for Benitec Biopharma on Strong BB-301 Clinical Results and Positive OutlookOctober 15, 2024 | markets.businessinsider.comBenitec Biopharma Announces Updated Investor Webcast InformationOctober 14, 2024 | globenewswire.comBenitec Reports Positive Phase 1b/2a Results For BB-301 In Oculopharyngeal Muscular DystrophyOctober 13, 2024 | markets.businessinsider.comBenitec Biopharma Reports Positive Data from Two Subjects Treated with Low-Dose BB-301 in Phase 1b/2a Study Presented at 29th Annual Congress of the World Muscle SocietyOctober 12, 2024 | globenewswire.comBenitec Biopharma's BB-301: Potential In OPMD But Still Too Early StagesOctober 9, 2024 | seekingalpha.comBenitec Biopharma (NASDAQ:BNTC) Shares Cross Above 50 Day Moving Average - What's Next?Benitec Biopharma (NASDAQ:BNTC) Stock Price Crosses Above 50-Day Moving Average - Time to Sell?October 9, 2024 | marketbeat.comBenitec Biopharma Stock (BNTC) Surges on Potentially Groundbreaking OPMD TreatmentOctober 3, 2024 | msn.comBenitec Biopharma (NASDAQ:BNTC) Stock, Short Interest ReportOctober 2, 2024 | benzinga.comBenitec Biopharma (NASDAQ:BNTC) Stock Quotes, Forecast and News SummaryOctober 2, 2024 | benzinga.comNantahala Capital Management LLC Buys New Shares in Benitec Biopharma Inc. (NASDAQ:BNTC)Nantahala Capital Management LLC purchased a new stake in shares of Benitec Biopharma Inc. (NASDAQ:BNTC - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 841,395 shares of the biotOctober 1, 2024 | marketbeat.comBuy Rating Affirmed for Benitec Biopharma on Strong Clinical Progress and Solid FinancialsSeptember 30, 2024 | markets.businessinsider.comSuvretta Capital Management's Strategic Acquisition in Benitec Biopharma IncSeptember 30, 2024 | finance.yahoo.comJMP Securities Reiterates Market Outperform Rating for Benitec Biopharma (NASDAQ:BNTC)JMP Securities reiterated a "market outperform" rating and issued a $16.00 target price on shares of Benitec Biopharma in a research note on Monday.September 30, 2024 | marketbeat.comBenitec Biopharma (NASDAQ:BNTC) Is In A Good Position To Deliver On Growth PlansSeptember 28, 2024 | finance.yahoo.comBenitec Biopharma Releases Full Year 2024 Financial Results and Provides Operational UpdateSeptember 26, 2024 | globenewswire.comBenitec Biopharma Inc. (NASDAQ:BNTC) Sees Significant Decline in Short InterestBenitec Biopharma Inc. (NASDAQ:BNTC - Get Free Report) saw a large decrease in short interest during the month of August. As of August 31st, there was short interest totalling 62,000 shares, a decrease of 6.8% from the August 15th total of 66,500 shares. Based on an average trading volume of 29,200 shares, the days-to-cover ratio is currently 2.1 days.September 18, 2024 | marketbeat.comBenitec Biopharma Announces Late Breaking Oral Abstract Presentation on BB-301 Phase 1b/2a Clinical Study at the 29th Annual Congress of the World Muscle SocietySeptember 18, 2024 | globenewswire.comBenitec Biopharma CEO to Participate in OPMD Awareness Day WebinarSeptember 17, 2024 | finance.yahoo.comGuggenheim Initiates Coverage of Benitec Biopharma (BNTC) with Buy RecommendationSeptember 12, 2024 | msn.comBenitec Biopharma (NASDAQ:BNTC) Receives New Coverage from Analysts at GuggenheimGuggenheim initiated coverage on shares of Benitec Biopharma in a research report on Thursday. They set a "buy" rating and a $17.00 price target for the company.September 12, 2024 | marketbeat.comBenitec Biopharma Inc. (NASDAQ:BNTC) Sees Large Decline in Short InterestBenitec Biopharma Inc. (NASDAQ:BNTC - Get Free Report) saw a large decrease in short interest during the month of July. As of July 31st, there was short interest totalling 68,000 shares, a decrease of 18.2% from the July 15th total of 83,100 shares. Based on an average daily trading volume, of 37,100 shares, the days-to-cover ratio is presently 1.8 days.August 17, 2024 | marketbeat.comBenitec Biopharma (NASDAQ:BNTC) Shares Pass Above Fifty Day Moving Average of $8.25Benitec Biopharma (NASDAQ:BNTC) Shares Pass Above 50 Day Moving Average of $8.25August 7, 2024 | marketbeat.comJanus Henderson Group PLC Has $1.27 Million Stock Holdings in Benitec Biopharma Inc. (NASDAQ:BNTC)Janus Henderson Group PLC lifted its position in Benitec Biopharma Inc. (NASDAQ:BNTC - Free Report) by 35.5% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 244,491 shares of the biotechnology company's stock after buyinAugust 7, 2024 | marketbeat.comBenitec Biopharma Inc. to Post FY2024 Earnings of ($5.45) Per Share, Leerink Partnrs Forecasts (NASDAQ:BNTC)Benitec Biopharma Inc. (NASDAQ:BNTC - Free Report) - Leerink Partnrs issued their FY2024 earnings estimates for Benitec Biopharma in a research report issued on Monday, July 22nd. Leerink Partnrs analyst M. Foroohar forecasts that the biotechnology company will post earnings of ($5.45) per shareJuly 24, 2024 | marketbeat.comBuy Rating on Benitec Biopharma: Anticipating BB-301’s Impact on OPMD Treatment and Stock ValueJuly 23, 2024 | markets.businessinsider.comLeerink Partners Initiates Coverage of Benitec Biopharma (BNTC) with Outperform RecommendationJuly 23, 2024 | msn.comBenitec Biopharma Share Price (BNTC.US)July 22, 2024 | lse.co.ukBenitec Biopharma (NASDAQ:BNTC) Now Covered by Analysts at SVB LeerinkSVB Leerink started coverage on shares of Benitec Biopharma in a research note on Monday. They set an "outperform" rating and a $13.00 price objective for the company.July 22, 2024 | marketbeat.comBenitec Biopharma Ltd ADR (BNTC)July 19, 2024 | investing.comBenitec Biopharma Reports Continued Durable Improvements in the Radiographic Assessments of Swallowing Efficiency and the Subject-Reported Outcome Instrument at the 180-Day Timepoint for First OPMD Subject Treated with Low-Dose BB-301 in Phase 1b/2a StudyJuly 15, 2024 | globenewswire.comShort Interest in Benitec Biopharma Inc. (NASDAQ:BNTC) Rises By 871.6%Benitec Biopharma Inc. (NASDAQ:BNTC - Get Free Report) saw a large growth in short interest in the month of June. As of June 30th, there was short interest totalling 92,300 shares, a growth of 871.6% from the June 15th total of 9,500 shares. Based on an average daily trading volume, of 97,700 shares, the short-interest ratio is presently 0.9 days. Approximately 4.1% of the company's stock are sold short.July 11, 2024 | marketbeat.comBenitec Biopharma Inc. (NASDAQ:BNTC) Sees Large Decrease in Short InterestBenitec Biopharma Inc. (NASDAQ:BNTC - Get Free Report) was the target of a significant decline in short interest during the month of June. As of June 15th, there was short interest totalling 9,500 shares, a decline of 25.8% from the May 31st total of 12,800 shares. Based on an average trading volume of 96,100 shares, the short-interest ratio is presently 0.1 days. Currently, 0.4% of the company's shares are short sold.June 29, 2024 | marketbeat.comBenitec Biopharma (NASDAQ:BNTC) Stock Passes Below 50 Day Moving Average of $7.93Benitec Biopharma (NASDAQ:BNTC) Stock Price Crosses Below 50 Day Moving Average of $7.93June 29, 2024 | marketbeat.comBenitec Biopharma (NASDAQ:BNTC) Share Price Passes Below Fifty Day Moving Average of $7.76Benitec Biopharma (NASDAQ:BNTC) Share Price Crosses Below Fifty Day Moving Average of $7.76June 21, 2024 | marketbeat.comBenitec Biopharma (NASDAQ:BNTC) Shares Pass Below 50 Day Moving Average of $7.34Benitec Biopharma (NASDAQ:BNTC) Stock Passes Below 50 Day Moving Average of $7.34June 6, 2024 | marketbeat.comBuy Rating for Benitec Biopharma on Promising Early-Stage Clinical Data and Solid FinancialsMay 20, 2024 | markets.businessinsider.comBenitec Biopharma (NASDAQ:BNTC) Shares Cross Above 50 Day Moving Average of $6.50Benitec Biopharma (NASDAQ:BNTC) Stock Price Crosses Above Fifty Day Moving Average of $6.50May 18, 2024 | marketbeat.com Get Benitec Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for BNTC and its competitors with MarketBeat's FREE daily newsletter. Email Address My Top Trump Rally Stocks (Ad)This Catalyst Hits Once Every 4 Years.. Every four years, on the day of the election, a catalyst is triggered. Over the last 20 years, this catalyst has caused 1,500 stocks to rise an average of 3,700%... within 90 days. And now, Tim Bohen is blowing the whole story wide open on Wednesday, November 20th at 8PM. Click here for details on your FREE RSVP. BNTC Media Mentions By Week BNTC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BNTC News Sentiment▼0.880.54▲Average Medical News Sentiment BNTC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BNTC Articles This Week▼71▲BNTC Articles Average Week Get Benitec Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for BNTC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies RNAC News CCCC News VALN News ORGO News FDMT News MGTX News AKBA News CGC News VYGR News SAGE News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BNTC) was last updated on 11/15/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Benitec Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Benitec Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.